Periorificial dermatitis

^[1]

Definition and Classification

Periorificial (perioral) dermatitis is a common inflammatory facial dermatosis characterised by persistent or recurrent clusters of small, monomorphic, erythematous micropapules and papulopustules distributed around the natural orifices of the face — most often the mouth (perioral), but also the nose (perinasal) and the eyes (periocular). The HALLMARK clinical sign is sparing of the vermilion border — the papules "usually leave a 1-2 mm Grenz zone around the red lips unaffected" (Chiriac 2025).^[1][3]

The terms perioral and periorificial are used interchangeably in clinical practice and in the literature, although purists reserve perioral for the strictly mouth-restricted disease and periorificial for the broader perioral + perinasal + periocular distribution. Most authorities — including the 2021 Searle review in J Cosmet Dermatol and the 2026 Acevedo-Fontanez synthesis in J Am Acad Dermatol — treat the two as a single clinicopathological entity and prefer periorificial dermatitis when perinasal or periocular involvement is present.^[1][3]

The relationship to rosacea and acne is debated. Periorificial dermatitis overlaps with papulopustular rosacea morphologically (red papules, papulopustules, midface distribution) but is distinct in three ways: (1) no comedones (unlike acne); (2) no telangiectasia, no flushing, no ocular rosacea in the typical case (unlike rosacea); and (3) a clear iatrogenic precipitant (topical corticosteroid, fluoridated toothpaste) in most patients. The relationship to TOPICAL STEROID DAMAGED FACE (TSDF) is closer than to rosacea — TSDF is the broader iatrogenic syndrome that includes periorificial dermatitis as its most recognisable phenotype, but also features diffuse erythema, telangiectasia, hypertrichosis, atrophy, and hyper- or hypopigmentation across the face.^[1][3][4]

The condition can be classified along five orthogonal axes that examiners test: ^[1]

A — By distribution

• Perioral (the most common distribution site) — papules clustered around the mouth, sparing the vermilion border.
• Perinasal (second most common) — papules around the alar grooves and nasal sill.
• Periocular / periorbital (less common, but tested) — papules around the lateral canthus and lower eyelid; must be distinguished from ocular rosacea, contact blepharitis, and demodicosis.
• Combined perioral + perinasal + periocular — when all three zones are involved, the disease is sometimes called periorificial dermatitis in the strict sense. ^[1]

B — By morphology

• Classic papulopustular — grouped erythematous micropapules and papulopustules on a background of erythema, often with fine scale.
• Granulomatous variant (Facial Afro-Caribbean Childhood Eruption — FACE) — monomorphic reddish-brown papules in prepubertal children, often with skin of colour; biopsy shows a granulomatous infiltrate (upper dermal and perifollicular — Kim 2011).^[13]
• Lupus miliaris disseminatus faciei-like (LMDF-like) — monomorphic reddish-brown dome-shaped papules, often periorbital; biopsies show "epithelioid granulomas ... in some cases, central caseous necrosis" (Nasimi 2025). ^[21]

C — By trigger

• Steroid-induced (most common) — chronic topical corticosteroid misuse on the face (over-the-counter in South Asia, prescribed for facial eczema / pityriasis in adolescents, compounded "fairness" creams in South-East Asia).
• Inhaled / nasal corticosteroid-induced — deposition of aerosolised steroid at the mouth and nose; rinse mouth after each actuation.
• Cosmetic / moisturiser-induced — heavy occlusive moisturisers, foundation, sunscreen (chemical UV filters), SLS-containing cleansers.
• Fluoridated-toothpaste-associated — historically a much-debated trigger; methodologically weak evidence but consistently reported.
• Idiopathic — the etiology is not completely understood; several triggers are proposed, including topical or inhaled corticosteroid exposure in the childhood granulomatous variant. ^[1]

D — By host

• Adult women (15-45 y) — the classic demographic (Mokos 2015); cosmetic, hormonal, and corticosteroid exposure.
• Children and adolescents — often granulomatous; may be related to inhaled corticosteroids, lip-licking, or fruit-juice contact.
• Patients with skin of colour — more prone to post-inflammatory hyperpigmentation and to the granulomatous variant.
• Pregnancy — tetracyclines and isotretinoin are contraindicated; the topical options are metronidazole or azelaic acid.
• Immunocompromised — consider demodicosis, candidiasis, and atypical infections (atypical mycobacteria, deep fungi). ^[1]

E — By severity (and management decision)

• Mild — in mild forms of perioral dermatitis, 'zero therapy' is the treatment of choice.
• Moderate — clustered papulopustules, cosmetic and psychosocial impact, may need oral tetracycline.
• Severe / refractory — extensive eruption, scarring dyspigmentation, treatment failure at 8-12 weeks; consider oral isotretinoin, biopsy to exclude alternative diagnoses. ^[1]

^{[1] [7] [9]}

Epidemiology and Risk Factors

Periorificial dermatitis is a common condition in dermatology outpatient practice. In a retrospective single-centre cohort of 1032 rosacea/POD patients, POD accounted for 18.5% of the group, an overall outpatient prevalence of 0.3% (vs 1.4% for rosacea); POD patients were younger and predominantly female.^[14] The classic form "primarily affects women aged 15 to 45 years" (Mokos 2015).^[6] In children POD is less common than in adults and is rare in infants and preschoolers; it has been documented from 3 months of age, with a slight predominance in girls.^[9][7]

Global patterns

The condition is reported worldwide, and the trigger mix differs by region: ^[1][22]

• Western Europe / North America / Australasia — predominantly prescription topical corticosteroid (medium- or high-potency prescribed for facial eczema, seborrhoeic dermatitis, or contact dermatitis and used long-term) and cosmetic / moisturiser overuse ("over-skincare" with occlusive day / night creams, sheet masks, sunscreens, retinoid-containing anti-ageing products).
• South Asia (India, Pakistan, Bangladesh, Sri Lanka, Nepal) — over-the-counter topical corticosteroid misuse drives the broader TOPICAL STEROID DAMAGED / DEPENDENT FACE (TSDF) phenotype. In a consecutive Indian TSDF cohort (n = 96), 64.6% of steroid products were obtained without prescription (most often on pharmacist recommendation), clobetasol propionate was the most-used steroid (44.8%), mean duration of use was 13.65 months, and hypopigmentation and cutaneous atrophy each affected 87.5%; melasma (40.6%), tinea (30.2%) and acne (25%) were the common indications. TSDF includes periorificial dermatitis among its manifestations, alongside diffuse facial erythema, atrophy, telangiectasia, hypertrichosis, and pigmentary change.^[22] The study authors call for stricter regulation of potent steroids, a ban on irrational fixed-dose combinations, and large-scale public and pharmacist education.^[22]
• Sub-Saharan Africa and the African diaspora — the granulomatous variant (FACE) is over-represented; prepubertal children, often with skin of colour.
• Latin America — fluoridated toothpaste and compounded fairness creams are additional triggers; melasma treatments containing unlabelled corticosteroids are a regional pitfall.
• East Asia (Korea, Japan, mainland China) — cosmetics and "K-beauty" multi-step skincare with multiple active ingredients can disrupt the barrier; high-potency whitening products occasionally contain unlabelled topical steroids. ^[1]

Recognised precipitants / triggers

The modern synthesis (Searle 2021; Acevedo-Fontanez 2026) groups the triggers into five categories that examiners test:^[1][3]

^[1]

Why women are disproportionately affected

Several factors compound in adult women: ^[1]

• Higher prevalence of cosmetic, moisturiser, and sunscreen use — the modern multi-step skincare routine.
• Greater exposure to prescription topical corticosteroids — prescribed for facial "eczema" or "dermatitis" by non-dermatologists and then continued long-term.
• Hormonal and physical factors — Mokos 2015 lists "various skin irritants, as well as other physical and hormonal factors" among the contributors.^[6]
• Higher prevalence of adult acne and rosacea — and the (mis)use of topical corticosteroids for both. ^[1]

Risk factor — over-the-counter topical corticosteroid misuse in South Asia

OTC topical corticosteroid misuse on the face is the single most important regional risk factor for periorificial dermatitis in South Asia — "abuse of topical corticosteroids (TCS) and 'fairness creams' on the face has become a significant dermatological problem in India, leading to a spectrum of adverse effects known as topical steroid-damaged/dependent face (TSDF)" (Sethi 2026). Non-prescription access (64.6% of a consecutive TSDF cohort, most often pharmacist-recommended) keeps the cycle going. Counsel patients and parents in plain language about the risks of OTC topical steroids on the face.^[22]

Pathophysiology

Periorificial dermatitis is best understood as a chronic, relapsing, barrier-driven inflammatory dermatosis in which a permissive barrier dysfunction is triggered and perpetuated by external insults — most prominently the iatrogenic misuse of topical corticosteroids.^[1][3]

Step 1 — Skin barrier dysfunction (the permissive lesion)

Epidermal barrier dysfunction is the underlying main pathogenic factor shared by the recognised triggers — irritants, physical factors, and hormonal factors (Mokos 2015). Barrier dysfunction is the substrate on which the triggers act; alone it is usually insufficient to cause disease.^[6]

Step 2 — Trigger exposure

The major triggers act through three mechanisms: ^[1]

1. Direct barrier disruption — SLS cleansers, retinoids, AHAs / BHAs, physical exfoliants, chemical sunscreen penetration.
2. Follicular occlusion with microbiome shift — heavy occlusive moisturisers, foundations, sheet masks, sunscreens in petrolatum base; Demodex mite overgrowth (their digestive enzymes and chitin exoskeletons are pro-inflammatory); Candida and Fusarium overgrowth (proposed but not confirmed).
3. Vasoactive and immunomodulatory effects — topical corticosteroid vasoconstriction with rebound vasodilation on withdrawal; chronic barrier inflammation with aberrant innate-immune activation (TLR-2, cathelicidin LL-37, kallikrein-related peptidases). ^[1]

Step 3 — Topical corticosteroid — the dominant iatrogenic trigger

Topical corticosteroids (especially medium-, high-, and super-high-potency such as betamethasone valerate, mometasone furoate, clobetasol propionate, halobetasol) cause periorificial dermatitis through a stereotyped sequence:^[4]

1. Initial vasoconstriction and immunosuppression — the corticosteroid binds the cytoplasmic glucocorticoid receptor, translocates to the nucleus, and trans-represses NF-κB and AP-1; pro-inflammatory cytokine transcription is suppressed; the cutaneous vasculature constricts. The patient experiences a misleading early improvement — the condition is "initially responsive to steroids" (StatPearls).^[15]
2. Epidermal and dermal atrophy — chronic use inhibits keratinocyte proliferation and collagen synthesis; the epidermis and dermis thin — atrophy is one of the most frequent cutaneous adverse effects of prolonged topical corticosteroid use (Hengge 2006).^[4]
3. Barrier dysfunction — stratum corneum integrity falls, transepidermal water loss rises, ceramide content falls.
4. Microbiome shift — the microbiome is one of the reviewed pathogenic factors in POD (Acevedo-Fontanez 2026); Demodex, Candida and fusobacteria have been proposed as co-factors without proven causality (Searle 2021).^[3][1]
5. Rebound on withdrawal — when the corticosteroid is stopped, the suppressed inflammation erupts as the rebound flare. The rebound phenomenon "usually develops after cessation of previous topical treatment" (Mokos 2015), and patients "should be forewarned that the condition will likely worsen until it improves" (StatPearls).^[6][15]

Step 4 — Why the vermilion border is spared

The vermilion border (the red margin of the lip) is characteristically uninvolved — the papules "usually leave a 1-2 mm Grenz zone around the red lips unaffected" (Chiriac 2025).^[9] Why the vermilion is spared is not established in the fetched literature: sources describe the sign without a proven mechanism. A proposed (but unproven) explanation is the structural distinctness of the vermilion — the absence of pilosebaceous follicles that host the occlusive and Demodex-related inflammation of the surrounding skin. Teach the sign as fact and the mechanism as hypothesis.^[9]

Step 5 — Inhaled / nasal corticosteroid mechanism

Inhaled corticosteroids (fluticasone, budesonide, beclomethasone, mometasone) used for asthma or allergic rhinitis deposit on the oropharyngeal and perioral mucosa with each actuation — inhaled corticosteroid exposure is a repeatedly reported POD trigger (Kellen 2017: "many patients have had recent exposure to a topical or less commonly an inhaled or systemic corticosteroid"). Two mechanisms contribute: ^[7]

1. Direct deposition — aerosolised steroid lands on the perioral skin and on the lip.
2. Salivary redistribution — steroid dissolved in saliva may be redistributed to the perioral skin by tongue and lip movements. ^[7]

The clinical advice is to rinse the mouth with water and wash the face after each actuation; spacer devices reduce oropharyngeal deposition; switching to a non-steroid preventer (leukotriene-receptor antagonist, tiotropium, biologic) avoids the problem. ^[1]

Step 6 — The Demodex / Candida / Fusarium debate

The role of Demodex folliculorum and Demodex brevis (commensal face mites) is correlated but not proven causal. Demodex mites "are believed to contribute to the pathogenesis of both rosacea and demodicosis"; standardised skin-surface biopsy (SSSB) is the standard quantification method, and a density >5 mites/cm² defines infestation ("Infestation was defined as at least 5 living parasites/cm2 of skin"; normal threshold "≤ 5 D/cm2" — Forton).^[20] Eradicating the mites (topical or oral ivermectin) does not always cure the disease. The current synthesis is that Demodex is a co-factor and biomarker of barrier dysfunction rather than a proven cause.^[1][3]

Candida and fusobacteria have been proposed as periorificial co-factors — Searle's 2021 systematic review explicitly searched "fusobacteria" among POD etiologies but concluded that "its etiology is not completely understood". Treat these organisms as permissive colonisers (of moist, barrier-disrupted skin) rather than proven causes.^[1]

Step 7 — Innate immunity and the cathelicidin pathway

Tetracyclines work here for their anti-inflammatory action, not their antibiotic action: "In the treatment of this condition, antibiotics are helpful for their anti-inflammatory properties" (StatPearls).^[15] The 2026 JAAD synthesis reviews pathogenesis through inciting factors, skin barrier dysfunction, inflammation, and the microbiome.^[3] Specific mediator cascades (cathelicidin, kallikreins, TLR-2) are extrapolated from rosacea research and are NOT established for periorificial dermatitis — do not quote them as POD fact.

Clinical Presentation

Periorificial dermatitis is a clinical diagnosis based on the triad of (1) morphology (grouped monomorphic micropapules and papulopustules), (2) distribution (perioral + perinasal + periocular with sparing of the vermilion border), and (3) history (a precipitating trigger, most often a topical corticosteroid).^[1][3][5]

The diagnostic clinical pattern

• Onset: weeks to months; often insidious but recognised suddenly by the patient when the eruption is finally visible in the mirror or on a photograph.

• Morphology: grouped, monomorphic, 1-2 mm erythematous micropapules and papulopustules. The lesions are uniform (not polymorphic as in acne) and superficial (not deep-seated as in rosacea nodules).^[1][3]

• Background: ill-defined erythema, often with fine scale, sometimes with telangiectasia in chronic disease.^[1]

• Distribution: perioral (around the mouth) is the most common; perinasal (around the alar grooves and nasal sill) is the second; periocular (around the lateral canthus and lower lid) is the third. Bilateral and symmetrical.^[1][3]

• Cardinal sign — sparing of the vermilion border: a narrow rim of clinically normal skin — the 1-2 mm Grenz zone around the red lips (Chiriac 2025) — typically separates the eruption from the lip margin. This is the single most useful diagnostic sign.^[1][3]

• Tempo: chronic and fluctuating; worse with continued corticosteroid use; rebounds after corticosteroid withdrawal.

• Demographics: young to middle-aged adult women are the typical demographic (Mokos 2015: "primarily affects women aged 15 to 45 years"); also seen in children, adolescents, and the elderly. ^[6]

Clinical course and timeline

The natural history, if untreated, is chronic and relapsing over months to years.^[15] With appropriate therapy, the verifiable time anchors are:^[2][15]

• After cessation: the rebound flare — "the rebound phenomenon usually develops after cessation of previous topical treatment" (Mokos 2015); counselling is critical in this window.^[6]
• From ~day 20: oral tetracycline "may improve physician-reported severity of POD from day 20 onwards" (low-certainty evidence, Gray 2022).^[2]
• 8-12 weeks: the standard tapering course for oral tetracycline/doxycycline/minocycline (StatPearls).^[15]
• Up to 3 months: "Topical therapies may not show peak efficacy until 3 months of daily treatment" (StatPearls) — so persistence, not early abandonment, is the aim.^[15]

Granulomatous variant — Facial Afro-Caribbean Childhood Eruption (FACE)

The granulomatous variant (also called Facial Afro-Caribbean Childhood Eruption, FACE, or granulomatous perioral dermatitis) is a clinicopathological variant of periorificial dermatitis seen in prepubertal children, often with skin of colour (Afro-Caribbean, Hispanic, South Asian, sub-Saharan African ancestry).^[3][5]

• Age: the granulomatous form is more common in childhood than in adulthood; periorificial dermatitis has been documented in children as young as 3 months.^[6][7]
• Sex: the granulomatous form affects mostly prepubescent boys, in contrast with the classic form, which primarily affects women aged 15-45 years.^[6]
• Distribution: papules cluster near the eyes, nose, and mouth; perinasal skin, nostrils, and eyelids can be involved.^[7][9]
• Morphology: monomorphic erythematous to flesh-coloured papules; pustules are rare.^[7]
• Trigger: many affected children have had recent exposure to a topical — or less commonly an inhaled or systemic — corticosteroid; a personal or family history of atopic disorders is frequent.^[7]
• Histology: a granulomatous subtype exists in addition to the classic variant; the histology of periorificial dermatitis otherwise resembles rosacea.^[1][7]
• Treatment: topical metronidazole has been successful in the paediatric population; topical calcineurin inhibitors are an effective, well-tolerated option; for more severe or extrafacial disease, oral antibiotics (tetracycline, doxycycline, minocycline, azithromycin, erythromycin) are used depending on the age of the patient.^[7][8]

Periocular variant

• Periocular involvement is recognised — "this disease can also affect the periocular and paranasal skin" (StatPearls).^[15]
• The lesions cluster around the eyelids; distinguish from ocular rosacea (blepharitis, meibomian gland dysfunction, conjunctival injection), contact blepharitis / eyelid dermatitis (patch test, itch predominates), and demodicosis (Demodex density >5/cm² on SSSB, cylindrical dandruff on the lash base).^[20]
• Treatment follows the standard ladder (topical anti-inflammatory ± oral tetracycline); refer to ophthalmology for ocular surface assessment. ^[15]

Paediatric variant (Chiriac 2025 update)

In infants and preschoolers, periorificial dermatitis presents with: ^[1]

• In infants and preschoolers POD is rare; the disease presents with monomorphic erythematous papules that "usually leave a 1-2 mm Grenz zone around the red lips unaffected"; perinasal skin, nostrils, and eyelids can be involved while extrafacial manifestations are rare (Chiriac 2025).^[9]
• Topical macrolides, azelaic acid, and calcineurin inhibitors are often used in mild cases; oral tetracyclines are the treatment of choice in more advanced cases — but tetracycline should be avoided in infants and preschoolers (bone and tooth calcification, permanent tooth discolouration).^[9]
• There are no randomised controlled trials of POD treatment in this age group; topical metronidazole or erythromycin and oral erythromycin are the most-used options.^[9]

Atypical presentations

• Predominantly periocular — see above.
• Lupus miliaris disseminatus faciei (LMDF)-like — monomorphic reddish-brown dome-shaped papules, often periorbital; histology shows epithelioid granulomas with (in some cases) central caseous necrosis.^[21] Believed by some to be on the spectrum with granulomatous periorificial dermatitis; by others to be a separate entity (LMDF) within the granulomatous rosacea spectrum.
• Perioral sarcoidosis — lupus pernio of the perioral skin; papules and plaques; biopsy shows non-caseating granulomas; systemic features (lungs, eyes, joints) should be sought. ^[1]

Differential Diagnosis

The diagnosis of periorificial dermatitis is clinical, but several conditions enter the differential. The cardinal features that distinguish each are summarised below.^[1][3][5]

The differential at a glance

^[1]

Cannot-miss differentials

Three differentials are dangerous to miss: ^[1]

1. Allergic contact dermatitis — the patient is often misdiagnosed as periorificial dermatitis, prescribed a topical corticosteroid, gets worse, and the cycle continues. Always ask about new toothpaste, lip balm, lipstick, foundation, sunscreen, fragrance, or topical antibiotics. Patch test if any doubt.
2. Perioral sarcoidosis — a single biopsy may be the only way to distinguish; consider if the patient has systemic features (cough, dyspnoea, arthralgia, uveitis, lymphadenopathy) or if the disease is recalcitrant.
3. Perioral squamous cell carcinoma — any chronic single-site perioral lesion in an older patient that is not responding to appropriate therapy warrants biopsy to exclude skin cancer (general dermatology safety principle).

Diagnostic pointers (high-yield)

• Sparing of the vermilion border — present in periorificial dermatitis.
• No comedones — periorificial dermatitis and rosacea; acne has comedones.
• No telangiectasia — periorificial dermatitis (typically); rosacea has telangiectasia.
• Perioral papules + inhaler use — inhaled-corticosteroid-induced periorificial dermatitis.
• Child with monomorphic centrofacial papules + skin of colour — granulomatous variant (FACE).
• Reddish-brown dome-shaped papules, often periorbital — LMDF.^[21]
• Single plaque on cheek / nose — granuloma faciale.
• Chronic single-site perioral lesion in an older patient — biopsy to exclude skin cancer.

Clinical and Bedside Assessment

The bedside assessment of suspected periorificial dermatitis has six steps that the examiner expects you to demonstrate. Each step has a yield — and each can be skipped only at the cost of missing a competing diagnosis.^[1][3]

Step 1 — Focused history (the diagnostic yield is high)

• Duration and tempo — weeks to months; chronic and fluctuating; worse with continued corticosteroid; rebound after corticosteroid withdrawal.
• Trigger inventory:
  • Topical corticosteroids — what strength (mild hydrocortisone / moderate clobetasone butyrate / potent betamethasone / super-potent clobetasol propionate); for how long; OTC or prescribed; which area of the face; frequency.
  • Inhaled / nasal corticosteroids — fluticasone, budesonide, beclomethasone, mometasone; mouth-rinsing habit.
  • Toothpaste — fluoride? SLS? whitening? charcoal? herbal? "natural"?
  • Cosmetics — foundation, concealer, primer, blush, bronzer, setting spray; how often applied; how often removed; with what cleanser.
  • Sunscreen — chemical (oxybenzone, avobenzone) vs physical (zinc oxide, titanium dioxide); in what base (lotion, cream, stick, spray, gel).
  • Skincare actives — retinoids (tretinoin, adapalene, retinol), AHAs (glycolic, lactic), BHAs (salicylic), vitamin C, niacinamide, peptides.
  • Moisturisers — heavy occlusive (petrolatum, lanolin, mineral oil) vs light (hyaluronic acid, glycerin).
  • Occupation — healthcare worker (hand hygiene + facial moisturiser), beautician (cosmetic exposure), food handler (citrus, garlic, flour), musician (wind instruments — lip contact), swimmer (chlorine), outdoor worker (sunscreen).
  • Hobbies — running, hot yoga (flushing), spicy food, alcohol.
• Drugs and medical history — EGFR-inhibitor therapy (cetuximab "has a high potential to cause acne-like rash" — an acneiform mimicker in oncology patients),^[25] hormone replacement / OCP, pregnancy.
• Family and social history — atopy (a personal or family history of atopic disorders is frequent in paediatric POD), rosacea, perioral dermatitis in close contacts.^[7]
• Prior treatments and response — what has been tried; what made it worse (most often a topical corticosteroid).
• Psychosocial impact — DLQI or similar; cosmetic and social impact; impact on work. ^[1]

Step 2 — Inspection of the affected area and all 20 nails (and the scalp)

• Affected area: grouped monomorphic micropapules and papulopustules, bilateral and symmetrical, on a background of erythema with fine scale.
• SPARING OF THE VERMILION BORDER — the cardinal sign. Confirm with the patient: "Are your lips involved?" The answer should be NO.
• Distribution zones: perioral, perinasal, periocular. Look at the glabella, chin, and cheeks for less common involvement.
• Background erythema and telangiectasia — telangiectasia suggests rosacea overlap; the disease is then often called rosacea + periorificial dermatitis and treated with a combined ladder.
• Atrophic features of TSDF — skin thinning (the skin is transparent, veins are visible), hypertrichosis, hyper- or hypopigmentation, striae (rare on the face but possible).
• All 20 nails — nail changes are uncommon in periorificial dermatitis, but onychomycosis and paronychia may coexist.
• Scalp and retroauricular — seborrhoeic dermatitis may coexist; look for scaly yellow scale.
• Eyes — blepharitis, conjunctival injection, meibomian gland dysfunction (ocular rosacea); refer to ophthalmology if present. ^[1]

Step 3 — Palpation and bedside manoeuvres

• Fluctuance — uncommon in periorificial dermatitis (the lesions are papulopustular, not abscess-forming); if fluctuance is present, consider secondary bacterial infection and swab.
• Diascopy — for the granulomatous variant (FACE), the apple-jelly colour of granulomas may be seen on pressure with a glass slide.
• Warmth and tenderness — present in acute flares; reduced in chronic quiescent disease.
• Cylindrical dandruff on lash base — Demodex cylindrical dandruff is a clue to demodicosis (and present in a minority of periorificial dermatitis patients).
• Tzanck smear / PCR — if vesicles are present, send HSV PCR to exclude herpetic involvement. ^[1]

Step 4 — Identify the portal of entry and the trigger

• The corticosteroid is the dominant iatrogenic trigger. Establish the strength, duration, area of application, and reason for original use. OTC use (South Asia, Gulf, Africa, Latin America) is common; do not be shy to ask.
• Toothpaste is a recognised chemical trigger. Ask about brand, fluoride, whitening additives, and SLS.^[16]
• The cosmetics and skincare routine — ask the patient to bring in their products, or photograph them; many are unlabelled or compounded.
• Inhaled / nasal corticosteroid use — ask about asthma, allergic rhinitis, COPD, and spacer use. ^[1]

Step 5 — Drug, disease, and pregnancy history

• Retinoid, EGFr / MEK / BTK inhibitor, antiretrovirals, hormone replacement, OCP, pregnancy, lactation.
• Diabetes, HIV, immunosuppression, atopy, rosacea, seborrhoeic dermatitis. ^[1]

Step 6 — Severity and psychosocial impact

• Severity — grade qualitatively: mild (scattered papules, no functional impact), moderate (clustered papulopustules, cosmetic / psychosocial impact), severe (extensive or refractory disease).^[1]
• Distribution — single zone vs multi-zone.^[1]
• Background erythema and scale — graded mild / moderate / severe.^[1]
• Psychosocial impact — DLQI; cosmetic impact; impact on social, work, and intimate life.^[1]

^[1]

Investigations

Periorificial dermatitis is a clinical diagnosis in the typical case. The role of investigations is to (1) exclude competing diagnoses when the morphology is atypical, (2) screen for underlying disease in refractory or recurrent disease, and (3) confirm the granulomatous variant when suspected.^[1][3][5]

Histology of classic periorificial dermatitis

The histology of classic periorificial dermatitis is non-specific: "Laboratory tests are not helpful in making the diagnosis, and the histology of POD resembles rosacea" (Kellen 2017).^[7] Reported changes are those of a mild perifollicular dermatitis — epidermal spongiosis with a superficial perivascular and perifollicular lymphohistiocytic infiltrate; no granulomas in the classic variant, no vasculitis, no microorganisms on special stains. ^[7]

The histology is helpful in distinguishing from: ^[1]

• Granulomatous rosacea / LMDF — "epithelioid granulomas with inflammatory cell infiltration and, in some cases, central caseous necrosis" (Nasimi 2025).^[21]
• Perioral sarcoidosis — well-formed non-caseating granulomas WITH systemic features (lung, eye, joints) — the systemic screen separates sarcoidosis from CGPD.
• Granuloma faciale — leukocytoclastic vasculitis with eosinophils and neutrophils.
• Pustular psoriasis / acrodermatitis continua — spongiform pustules of Kogoj in the epidermis. ^[1]

Histology of the granulomatous variant (FACE / CGPD)

• Dermis: CGPD is "characterized by monomorphous, small, papular eruptions around the mouth, nose and eyes that histopathologically show a granulomatous pattern" — an upper dermal and perifollicular granulomatous infiltrate (Kim 2011).^[13]
• Cultures are invariably negative and systemic involvement is absent — the features that separate CGPD from sarcoidosis and infection (Lucas 2009).^[28]
• Special stains (AFB, Fite, GMS, PAS) — negative (exclude mycobacteria and fungi). ^[13]

Patch testing

Patch testing is indicated when: ^[1]

• The lips are involved (suggests contact dermatitis from toothpaste, lip balm, lipstick, topical antibiotic).
• The morphology is eczematous rather than papulopustular.
• The patient has a history of multiple product changes.
• Standard therapy has failed. ^[1]

The standard series (European / North American baseline) plus a dental series and a cosmetic / fragrance series is the typical panel; specific allergens (metals, fragrance mix, balsam of Peru, preservatives) are reported in dental materials and lip products — in a multicentre perioral/oral patch-test cohort, nickel sensitization was 28.6% and balsam of Peru 11.4% (Forkel 2024).^[26]

Dermoscopy (dermatoscopy)

No dermoscopic pattern specific to periorificial dermatitis is established — the diagnosis is clinical (Kellen 2017).^[7] Non-specific findings (background erythema, fine scale, perifollicular change) may be seen; suspected demodicosis is quantified by standardised skin-surface biopsy (>5 mites/cm² defines infestation).^[20]

KOH and fungal culture

KOH preparation and fungal culture are indicated when: ^[1]

• The lesion is at the corner of the mouth (angular cheilitis) — Candida dominant.
• The patient is immunocompromised.
• The patient is a chronic oral or inhaled corticosteroid user.
• Refractory disease — systemic isotretinoin should be considered for patients refractory to all standard therapies. ^[1]

Demodex quantification

Demodex quantification is indicated when: ^[1]

• The disease is refractory to standard therapy.
• The patient has rosacea-like features with high suspicion of demodicosis.
• The patient is immunocompromised (HIV, transplant, chemotherapy).
• Cylindrical dandruff is present on the lash base. ^[1]

Methods: standardised skin-surface biopsy (SSSB) with cyanoacrylate glue; skin scraping with a scalpel and immersion oil; modified standardized skin surface biopsy (1 cm² of stratum corneum lifted and examined under light microscopy). A density of ≥5 mites per cm² is suggestive of demodicosis. ^[1]

Management — Resuscitation

Periorificial dermatitis is not a dermatological emergency; resuscitation is rarely needed. The role of the first consultation is to: ^[1]

1. Establish the diagnosis — check the morphology and distribution, look for sparing of the vermilion border, and take a trigger history.
2. Discontinue the offending trigger — most importantly the topical corticosteroid.
3. Counsel on the rebound flare — the patient must understand that the rash will likely worsen before it improves ("patients should be forewarned that the condition will likely worsen until it improves with the initiation of appropriate therapies" — StatPearls); the un-forewarned patient restarts the steroid and perpetuates the cycle.^[15]
4. Initiate the management ladder — see "Management — Definitive and Stepwise" below.
5. Safety-net — forewarn patients that the condition will likely worsen until it improves with appropriate therapy, and that topical therapies may not show peak efficacy until 3 months of daily treatment. ^[1]

Same-day specialist referral indications

• Diagnostic uncertainty (granulomatous variant vs sarcoidosis vs LMDF; rosacea vs periorificial dermatitis; cutaneous lymphoma).
• Severe flare with significant psychosocial impact.
• Pregnancy, lactation, or planned pregnancy.
• Child (especially prepubertal — consider granulomatous variant and biopsy).
• No response despite an adequate treatment course — note that oral tetracyclines are prescribed as an 8 to 12 week tapering course and topical therapies may not show peak efficacy until 3 months of daily treatment.
• Recurrence despite trigger avoidance.
• Ocular involvement with vision changes (refer to ophthalmology urgently).
• Single chronic lesion in an older patient (rule out SCC). ^[1]

Psychological support

Periorificial dermatitis is cosmetically and psychologically distressing; patients are often misdiagnosed and given more topical corticosteroid, which perpetuates the cycle; and the rebound flare is psychologically devastating without prior warning. Validate the experience, acknowledge the cosmetic impact, and offer realistic timeframes for improvement. Consider DLQI monitoring and referral for psychological support if distress is significant. ^[1]

Management — Definitive and Stepwise

The management of periorificial dermatitis is anchored on three principles and a staged ladder that mirrors rosacea management. The principles are: ^[1]

1. Stop the trigger. The corticosteroid (and the toothpaste, cosmetics, occlusive moisturisers, SLS cleansers) must be removed.
2. Zero therapy in mild disease. In mild forms, zero therapy is the treatment of choice; sunscreens are themselves a reported trigger, so review any product already in use.
3. Calm the inflammation. Topical anti-inflammatory (metronidazole / azelaic acid / calcineurin inhibitor) for mild-moderate disease; oral tetracycline for moderate-severe. ^[1]

The staged ladder is presented in the figure and elaborated below.^[1][2][3][5]

^[6]

• Discontinue ALL topical products on the face:
  • Topical corticosteroids (non-negotiable — the dominant iatrogenic trigger).
  • Cosmetics — foundation, concealer, primer, blush, bronzer, setting spray.
  • Heavy moisturisers — petrolatum, lanolin, mineral oil, dimeticone in an occlusive base.
  • Toners, exfoliants, and actives — retinoids, AHAs, BHAs, vitamin C, niacinamide, peptides.
  • Sunscreens with chemical UV filters in an occlusive base.
  • SLS-containing cleansers — switch to a non-foaming, SLS-free cleanser.
• Review the toothpaste — fluorinated toothpaste is a recognised trigger of periorificial dermatitis.
• Expect a rebound flare after stopping corticosteroids — "abrupt discontinuation may lead to rebound flaring, and patients should be forewarned that the condition will likely worsen until it improves with the initiation of appropriate therapies"; if the patient has been using a medium- to high-potency steroid, it may need to be slowly weaned by using a low-potency steroid (e.g., hydrocortisone cream) (StatPearls).^[15] Counsel in plain language: warn that the flare is expected after stopping the steroid and that the condition will likely worsen until the appropriate therapy takes effect, so the steroid is not restarted.^[15]
• Stop adding further topicals in mild disease — zero therapy is the treatment of choice.
• Review any sunscreen in use — sunscreens are a reported trigger of periorificial dermatitis.
• Zero therapy — in mild forms, discontinuing the inciting topicals is the treatment of choice; epidermal barrier dysfunction is a shared pathogenic factor, not a licence to add further products.

Step 2 — Topical anti-inflammatory (mild-moderate disease)

Timing varies — zero therapy alone is the treatment of choice for mild disease; add a topical anti-inflammatory for moderate disease (the Mokos ladder).^[6]

• Topical metronidazole gel, cream, or lotion (0.75% gel has POD trial data) — a first-line topical option (StatPearls); anti-inflammatory action. In pregnancy use with specialist input (no POD-specific pregnancy trial). No large perioral-specific RCT exists in the 2022 systematic review.^[15][2]
• Topical azelaic acid gel — a first-line topical option (StatPearls); anti-inflammatory and depigmenting (relevant where post-inflammatory hyperpigmentation is a concern). Caveat: azelaic acid gel "may result in no change in either physician- or patient-reported severity after 6 weeks of treatment" (Gray 2022, low certainty).^[15][2]
• Topical calcineurin inhibitors — pimecrolimus cream or tacrolimus ointment, twice daily — "can also be effective" (StatPearls); steroid-sparing anti-inflammatory. In paediatric POD: complete response in 68.8% with TCI alone, adverse events "rare and mild" (Ollech 2020). Transient burning or stinging is common; use age-appropriate strengths in children.^[15][8]
• Ivermectin — topical (with a single dose of oral) ivermectin was "employed successfully" in a treatment-resistant childhood granulomatous POD case (Correia 2026); consider when Demodex density is high or the granulomatous variant resists therapy.^[27]
• Topical erythromycin gel or clindamycin lotion/gel — first-line topical options (StatPearls); erythromycin is the standard oral alternative when tetracyclines are contraindicated (children <8 y, pregnancy, nursing).^[15]
• Topical adapalene — improvement "demonstrated" (StatPearls), but an irritant on a barrier-disrupted face — introduce cautiously after the acute flare.^[15]

Step 3 — Oral therapy (moderate-severe or refractory disease)

Indications: extensive eruption, failure of zero therapy + topical anti-inflammatory, or severe psychosocial impact (remember that topicals "may not show peak efficacy until 3 months of daily treatment" — StatPearls). ^[15]

• Oral tetracyclines (the best-validated systemic therapy):
  • Oral tetracycline reveals the best valid evidence of any systemic agent for perioral dermatitis; in more severe disease the best-validated choice is oral tetracycline in a subantimicrobial dose until complete remission is achieved.^[5][6]
  • In the systematic review of pharmacological interventions, oral tetracycline may improve physician-reported severity of POD from day 20 onwards (low-certainty evidence); adverse effects may include abdominal discomfort, facial dryness, and pruritus.^[2]
  • Named oral-antibiotic alternatives used depending on the age of the patient: doxycycline, minocycline, azithromycin, and erythromycin.^[7]
  • Dosing (StatPearls): tetracycline 250-500 mg twice a day, doxycycline 100 mg once or twice a day, or minocycline 100 mg once or twice a day, "for an 8 to 12 week tapering course"; topical therapy runs concurrently, and "topical therapies may not show peak efficacy until 3 months of daily treatment".^[15]
• Oral therapy in young children (tetracycline not suitable):
  • Oral tetracycline may not be suitable if the patient is under 8 years old.^[5]
  • In infants and preschoolers tetracyclines should be avoided altogether — they can affect the calcification (hardening) of the bones and teeth and lead to permanent tooth discolouration; there are no randomised controlled trials in this age group, and topical metronidazole or erythromycin and oral erythromycin are the most-used options.^[9]

Step 4 — Refractory disease (rare)

Reserved for patients who fail zero therapy + topical anti-inflammatory + oral tetracycline. ^[1]

• Systemic isotretinoin — should be considered as a therapeutic option for patients refractory to all standard therapies; a 2026 case report of recalcitrant perioral dermatitis resistant to multiple topical and systemic therapies achieved complete remission with low-dose isotretinoin maintenance, supporting an antibiotic-sparing strategy in selected patients.^[6][11]
• Topical roflumilast 0.3% cream — a phosphodiesterase-4 inhibitor cream approved in 2022 for chronic plaque psoriasis (including intertriginous areas); an illustrative case study of adult periorificial dermatitis cleared in 5 days with once-daily use, without adverse events or recurrence at 11 months — case-study-level evidence only, not yet first-line.^[10]
• Specialist referral — to a dermatology clinic with experience in refractory facial dermatoses.

Step 5 — Specific subtype management

• Granulomatous variant (childhood) — topical metronidazole has been successful in paediatric POD; topical calcineurin inhibitors are effective and well tolerated (complete response in 68.8% of children treated with TCI alone in the largest cohort); for more severe or extrafacial disease, oral antibiotics are chosen depending on the age of the patient — oral clarithromycin cleared 95.4% (41/43) of childhood granulomatous POD at 6 months (median 10-week course; scarring in 14.6% of moderate-to-severe cases).^[7][8][23]
• Corticosteroid-induced (including inhaled) — many patients have had recent exposure to a topical — or less commonly an inhaled or systemic — corticosteroid; steroids may initially control the skin lesions, but disease often rebounds after discontinuing therapy, so stop the corticosteroid and anticipate the rebound.^[7]
• Azelaic acid — listed among the promising treatment options requiring further research; in the systematic review, azelaic acid gel resulted in no change in physician- or patient-reported severity after 6 weeks of treatment.^[1][2]

Step 6 — Maintenance and trigger avoidance

• Do not add further topicals in mild disease — zero therapy is the treatment of choice.
• Physical sunscreen (zinc oxide / titanium dioxide) — daily, SPF 30-50, reapply every 2 hours.
• Trigger avoidance — non-fluoride toothpaste; SLS-free cleanser; minimal cosmetics; no facial topical corticosteroid (hydrocortisone 1% only for short, defined courses, or to wean off a more potent steroid).
• Do not stop the oral tetracycline abruptly — in more severe disease it is the best validated choice, and physician-reported severity improves from day 20 onwards on low-certainty evidence.^[15]
• Recurrence — repeat the same ladder; oral tetracycline can be restarted for a second course. ^[1]

Key principles (high-yield)

• Never use potent or moderate topical corticosteroids on the face — they worsen periorificial dermatitis (and rosacea) and produce rebound on withdrawal. For facial eczema, use topical calcineurin inhibitors instead.^[4]
• Warn about the rebound flare — the rash will likely worsen before it improves; a forewarned patient does not restart the steroid.^[15]
• Give therapy time — topical therapies "may not show peak efficacy until 3 months of daily treatment" (StatPearls); the childhood granulomatous variant runs for months and resolves without scarring.^[15][13]
• Avoid the reported triggers — fluorinated toothpaste, facial, inhaled or nasal corticosteroid, chewing gum, dental materials, cosmetics and sunscreens are all reported triggers.

^{[1] [5] [6]}

Specific Subtypes and Scenarios

A — Granulomatous variant (Facial Afro-Caribbean Childhood Eruption, FACE)

• Demographics: the granulomatous subtype is more common in small children than in adults and affects mostly prepubescent boys; POD has been documented in children as young as 3 months, with a slight predominance in girls overall.^[9][6][7]
• Morphology: monomorphic erythematous to flesh-coloured papules; pustules are rare.^[7]
• Distribution: papules near the eyes, nose, and mouth; perinasal skin, nostrils, and eyelids can be involved.^[7][9]
• Trigger: many affected children have had recent exposure to a topical — or less commonly an inhaled or systemic — corticosteroid; a personal or family history of atopic disorders is frequent.^[7]
• Histology: a granulomatous subtype exists in addition to the classic variant; the histology of POD otherwise resembles rosacea.^[1][7]
• Treatment: topical metronidazole (successful in paediatric POD); topical calcineurin inhibitors (effective and well tolerated — complete response in 68.8% with TCI alone); age-appropriate oral antibiotics (tetracycline, doxycycline, minocycline, azithromycin, erythromycin). Oral tetracycline may not be suitable under 8 years.^[7][8][5]

B — Inhaled / nasal corticosteroid-induced periorificial dermatitis

• Demographics: asthmatic / allergic-rhinitis / COPD patients using fluticasone, budesonide, beclomethasone, or mometasone.
• Distribution: perioral (lip-licking redistribution) and perinasal (deposition around the nares).
• Treatment: rinse mouth and wash face after each actuation; use a spacer device; consider non-steroid preventer (leukotriene antagonist, tiotropium, omalizumab, dupilumab, mepolizumab). Continue management ladder (zero therapy for the face + topical anti-inflammatory + oral tetracycline if needed). ^[1]

C — Pregnancy and lactation

• Principle — management demands "special consideration for maternal and fetal safety" (Yang 2016); POD-specific pregnancy trials do not exist (Gray 2022 — data are required for children and special populations).^[12][2]
• Oral tetracyclines — contraindicated in pregnancy and in nursing mothers (StatPearls); tetracyclines are "class D drugs, contraindicated in pregnancy and in children under 8 years of age" (Cross 2016); doxycycline "should not be used in pregnant women because of risk of permanent tooth discolouration and possible impact on bone formation in the fetus" (Smith 2012).^[15][17][18]
• Oral erythromycin — the standard oral alternative when tetracyclines are contraindicated: 250-500 mg daily (StatPearls).^[15]
• Isotretinoin — "a potent teratogen and therefore contraindicated in pregnancy"; a pregnancy-prevention programme (effective contraception; pregnancy testing before and during therapy) is mandatory in women of childbearing potential.^[19]
• Topicals — the general first-line topical options (metronidazole, azelaic acid, calcineurin inhibitors) are used with specialist input; favour the least-exposure effective option.^[15]

D — Immunocompromised patients

• Diagnosis stays clinical — laboratory tests are not helpful in making the diagnosis of POD, and the histology resembles rosacea; it is important to rule out other acneiform diagnoses based on the age of the patient, clinical history, and presentation of the lesions.^[7]
• Differentials that matter — atopic and seborrheic dermatosis, paediatric rosacea, juvenile acne, and cutaneous sarcoidosis (children); persistent acne is the major differential in adults.^[9]
• Refractory or atypical disease — reconsider the diagnosis and exclude mimickers rather than escalating empirical therapy; no therapy is FDA-approved specifically for POD.^[3]

E — Skin of colour (Fitzpatrick IV-VI)

• Post-inflammatory hyperpigmentation is a major concern; azelaic acid is dual-action (anti-inflammatory + depigmenting) — noting the low-certainty null finding for POD severity at 6 weeks (Gray 2022).^[2]
• Granulomatous variant (FACE) is over-represented; biopsy to confirm; treat with topical metronidazole or pimecrolimus and oral macrolides.
• TSDF is more visible on darker skin — hypopigmentation, hyperpigmentation, and atrophy are more cosmetically impactful.
• Sunscreen caution — sunscreens are among the reported triggers of periorificial dermatitis, so review any product already in use. ^[1]

F — Periorificial dermatitis in the elderly

• Rosacea overlap is common; combined rosacea + periorificial dermatitis treated with combined ladder.
• Topical corticosteroid misuse history is often long (years to decades); psychological and education component is large.
• Tetracyclines are tolerated but review co-medication for interactions.
• Isotretinoin is an option for refractory disease. ^[1]

Complications and Pitfalls

Disease-related complications

• Persistent erythema and telangiectasia — chronic disease can lead to telangiectasia; pulsed-dye laser or IPL for cosmetic improvement.
• Post-inflammatory hyperpigmentation — major concern in skin of colour; early anti-inflammatory control and azelaic acid reduce the pigmentary legacy.
• Post-inflammatory hypopigmentation — uncommon but reported after severe flares, especially in dark skin.
• Scarring — rare in classic POD (unlike acne); in childhood granulomatous POD, however, "Scarring (14.6%) occurred only in moderate-to-severe cases" (Xiao 2025) — a reason not to undertreat severe granulomatous disease.^[23]
• Psychosocial distress — DLQI is high; the cosmetic impact is severe and the rebound flare without prior warning is psychologically devastating.
• Secondary bacterial infection — S. aureus or Streptococcus; culture and antibiotics. ^[1]

Treatment-related pitfalls

• Corticosteroid rebound — a common pitfall: clinicians often misdiagnose perioral dermatitis and inappropriately prescribe topical corticosteroids, which worsen the condition over time. Corticosteroid cream can improve the clinical picture, but there is a risk of rebound when treatment is stopped; in the initial treatment period, patients with steroid-induced perioral dermatitis should be closely followed up because the rebound phenomenon usually develops after cessation of previous topical treatment.^[5][6]
• Corticosteroid as cause, not cure — the strongest evidence implicates topical corticosteroid misuse as the principal causative factor in POD pathogenesis; whether corticosteroid is a good treatment or a cause remains the clinical question to get right.^[1][5]
• Antibiotic choice by age — oral tetracycline may not be suitable under 8 years, and tetracyclines should be avoided in infants and preschoolers (they affect bone and tooth calcification and can cause permanent tooth discolouration); age-appropriate alternatives include erythromycin and azithromycin.^[5][9][7]
• Tolerability of systemic therapy — adverse effects of oral tetracycline may include abdominal discomfort, facial dryness, and pruritus (low-certainty evidence).^[2]
• Calcineurin inhibitor safety — adverse events with topical calcineurin inhibitors were rare and mild in the largest paediatric cohort (132 patients).^[8]

Diagnostic pitfalls

• Mistaking periorificial dermatitis for eczema / contact dermatitis and prescribing more topical corticosteroid — the most common diagnostic error worldwide. The cycle is: eczema → topical steroid → apparent improvement → tolerance → rebound → "more eczema" → more topical steroid → periorificial dermatitis → topical steroid → worsening. Look for the cardinal sign of sparing of the vermilion border together with a history of topical corticosteroid use.
• Mistaking periorificial dermatitis for rosacea and prescribing topical corticosteroid — the same cycle, the same trap. The presence of telangiectasia, flushing, and ocular rosacea is in favour of rosacea, but the periorificial distribution and the corticosteroid history favour periorificial dermatitis.
• Missing allergic contact dermatitis — lip involvement, itch, and a new product are clues. Patch test.
• Missing the granulomatous variant — the morphology and demographic are different; biopsy to confirm.
• Missing perioral sarcoidosis — single biopsy is diagnostic; consider if systemic features are present.
• Missing LMDF — dome-shaped, often-periorbital reddish-brown papules, with epithelioid granulomas and (in some cases) central caseous necrosis on biopsy, are diagnostic. ^[21]

The "never do" list

• Avoid topical corticosteroids on the face — facial use commonly precedes this condition and inappropriate use worsens it over time; medium- to high-potency steroids may need to be slowly weaned using a low-potency steroid (eg, hydrocortisone cream).** The only acceptable facial topical corticosteroid is 1% hydrocortisone, for short defined courses only (acute contact dermatitis, acute eczema) or to wean a patient off a more potent steroid.
• Never incise a perioral pustule. The lesions are papulopustular, not abscess-forming; incision produces scarring and does not help.
• Do not treat cultured Candida as the primary cause. Candida and Fusarium overgrowth are proposed contributors, not confirmed causes; a positive culture alone does not redirect therapy away from barrier restoration and trigger removal.^[1]
• Complete the oral tetracycline course — tetracyclines are prescribed as an 8 to 12 week tapering course; in severe disease the best validated choice is oral tetracycline in a subantimicrobial dose until complete remission is achieved.** Complete an 8-12 week tapering course; transition to topical maintenance.^[15]
• Never forget to counsel on the rebound flare. Patients should be forewarned that the condition will likely worsen until it improves with the initiation of appropriate therapies for perioral dermatitis. ^[1]

^[1]

Prognosis and Disposition

Natural history

Untreated, periorificial dermatitis is chronic and relapsing over months to years; steroid withdrawal can leave "chronic, recurrent disease" (StatPearls).^[15] Treatment success rests on removal of the trigger (the corticosteroid) and counselling through the rebound flare; failure follows the reverse. ^[6]

With treatment

• Expect improvement on a scale of weeks to months, not days — oral tetracycline "may improve physician-reported severity of POD from day 20 onwards" (low certainty);^[2] the oral course is an 8-12 week taper, and topical therapies "may not show peak efficacy until 3 months of daily treatment" (StatPearls).^[15]
• Granulomatous variant (FACE / CGPD) — "typically persists for several months but resolved without scarring" (Kim 2011); it is "ultimately self-limited" (Lucas 2009).^[13][28]

Recurrence

• POD runs as "chronic, recurrent disease", particularly when topical steroids are restarted or triggers persist (StatPearls).^[15]
• Taper oral therapy to topical maintenance, and practise long-term trigger avoidance (non-fluoride toothpaste, no facial corticosteroid, minimal cosmetics) — the cornerstone of secondary prevention. ^[6]

Disposition

• Outpatient management is the rule.
• GP + dermatologist for severe, refractory, or diagnostic-uncertain disease.
• Specialist referral (dermatology) for: severe disease, granulomatous variant, child, pregnancy, treatment failure at 8-12 weeks, suspected alternative diagnosis.
• Ophthalmology referral for ocular involvement (blepharitis, conjunctival injection, meibomian gland dysfunction).
• Infectious diseases referral for atypical mycobacterial or deep fungal infection in immunocompromised patients.
• Plastic / dermatologic surgery for pulsed-dye laser or IPL for persistent telangiectasia and erythema. ^[1]

Follow-up schedule

• Week 0 — initial consultation; trigger removal; counselling on rebound flare; topical anti-inflammatory or oral tetracycline prescribed.
• Early follow-up (initial treatment period) — patients with steroid-induced periorificial dermatitis should be closely followed up because the rebound phenomenon usually develops after cessation of previous topical treatment.
• Week 4 — review; assess response; escalate if no improvement.
• Week 8 — review; assess response; consider biopsy if no improvement.
• Week 8-12 (end of tetracycline course) — the standard oral tetracycline course is an 8 to 12 week taper; topical therapies may not show peak efficacy until 3 months of daily treatment.
• Week 24 — final review; safety-net advice; long-term plan. ^[1]

Safety-net advice for patients

• Avoid topical corticosteroids on the face — facial topical corticosteroid use commonly precedes this condition, and inappropriate use worsens the condition over time.** Hydrocortisone 1% only, short defined courses (acute contact dermatitis, acute eczema) or to wean off a more potent steroid.
• Switch to non-fluoride, SLS-free toothpaste.
• Review cleansers already in use — cosmetics and facial products are reported triggers.
• Review any sunscreen in use — sunscreens are a reported trigger of periorificial dermatitis.
• Do not add a moisturiser as treatment — zero therapy is the treatment of choice in mild disease.
• Rinse the mouth and face after each inhaled / nasal corticosteroid actuation.
• Return if the disease recurs despite compliance — repeat the ladder; consider biopsy if atypical. ^[1]

Special Populations

Children

• Demographics — POD has been documented in children as young as 3 months, with a slight predominance in girls compared with boys; many children have a personal or family history of atopic disorders. In infants and preschoolers POD is rare, and the granulomatous subtype is more common in small children than in adults.^[7][9]
• Trigger — many children have had recent exposure to a topical — or less commonly an inhaled or systemic — corticosteroid; topical corticosteroid use on the face commonly precedes the eruption.^[7][5]
• Granulomatous variant (FACE) — the granulomatous form is more common in childhood than in adulthood and affects mostly prepubescent boys.^[6][9]
• Treatment — topical metronidazole has been successful in the paediatric population; topical calcineurin inhibitors are effective and well tolerated; for extrafacial lesions or more severe disease, oral antibiotics (tetracycline, doxycycline, minocycline, azithromycin, erythromycin) are used depending on age — oral tetracycline may not be suitable under 8 years and tetracyclines are avoided in infants and preschoolers (bone and tooth calcification; permanent tooth discolouration); topical metronidazole or erythromycin and oral erythromycin are the most-used options in that age group.^[7][8][5][9]
• Evidence — there are no randomised controlled trials of POD treatment in infants and preschoolers; the overall POD treatment evidence base is low to very low certainty.^[9][2]

Pregnancy

• Course in gestation — perioral dermatitis is among the inflammatory and glandular skin diseases whose course can change in pregnancy (glandular activity fluctuates), but courses are diverse and do not always follow the predicted pattern.^[12]
• Management principle — therapy in pregnancy demands special consideration of maternal and fetal safety; reviews of POD management in pregnancy approach each drug on that basis rather than through POD-specific trials.^[12]
• Evidence base — no POD-specific randomised trial informs drug choice in pregnancy; the general POD treatment evidence base is low to very low certainty, so favour the least-exposure effective option and specialist input.^[2]

Elderly

• Rosacea overlap is common.
• Topical corticosteroid misuse history often extends years to decades.
• Tetracyclines are tolerated but review co-medication for interactions.
• Isotretinoin is an option for refractory disease.
• Demodicosis is over-represented in the elderly (rosacea-like features with high Demodex density); consider topical ivermectin 1% or oral ivermectin. ^[1]

Immunocompromised

• HIV — broaden the differential; screen for concurrent infections; biopsy if atypical.
• Transplant — high topical steroid exposure (used as part of immunosuppressive regimen for skin conditions); drug interactions with tetracyclines (e.g., calcineurin inhibitor levels).
• Chemotherapy / biologics — broader differential (atypical mycobacteria, deep fungi); biopsy if refractory. ^[1]

Skin of colour (Fitzpatrick IV-VI)

• Post-inflammatory hyperpigmentation — azelaic acid gel may result in no change in either physician- or patient-reported severity after 6 weeks of treatment, so it is not a reliable answer here.
• Granulomatous variant (FACE) is over-represented; biopsy to confirm; treat with topical metronidazole or pimecrolimus and oral macrolides.
• TSDF is more visible — hypopigmentation, hyperpigmentation, and atrophy are more cosmetically impactful. ^[1]

Patients using inhaled / nasal corticosteroids

• Asthma, allergic rhinitis, COPD — rinse mouth and wash face after each actuation; spacer device; consider non-steroid preventer (leukotriene antagonist, tiotropium, omalizumab, dupilumab, mepolizumab).
• Distinguish from perioral allergic contact dermatitis — the lip-licking redistribution can produce both perioral and perinasal periorificial dermatitis and perioral contact cheilitis. ^[1]

Evidence, Guidelines and Controversies

Mokos 2015 — the staged therapeutic ladder (Acta Clin Croat)

• Mild disease — 'zero therapy' is the treatment of choice, with patient education and continuous psychological support; follow steroid-induced patients closely in the initial period because the rebound phenomenon usually develops after cessation of previous topical treatment.
• Moderate disease — topical metronidazole, erythromycin, and pimecrolimus.
• More severe disease — the best-validated choice is oral tetracycline in a subantimicrobial dose until complete remission is achieved.
• Refractory to all standard therapies — systemic isotretinoin should be considered. ^[6]

US perspective — Acevedo-Fontanez 2026 (J Am Acad Dermatol)

• Disease concept — periorificial dermatitis is a chronic papulopustular facial dermatitis; its etiology remains incompletely understood and no therapies are FDA-approved specifically for POD.
• Pathogenesis reviewed — inciting factors, skin barrier dysfunction, inflammation, and the microbiome.
• Diagnosis — the diagnostic features and their distinction from clinical mimickers are reviewed.
• Treatment — skincare measures plus topical and systemic therapies are discussed; given the absence of approved therapies, management is off-label and evidence-guided.^[3]

Paediatric TCI evidence and the treatment review (Ollech 2020; Tempark 2014)

• Topical pimecrolimus is effective and well tolerated in paediatric periorificial dermatitis (Ollech 2020 retrospective cohort, n = 132 — a US single-centre series, not a European guideline).^[8]
• Oral tetracycline "reveals the best valid evidence" among systemic options (Tempark 2014).^[5]
• Calcineurin inhibitors — topical calcineurin inhibitors (tacrolimus ointment, pimecrolimus cream) can also be effective; pimecrolimus is an option in moderate disease and may improve physician-reported severity slightly after 4 weeks (low certainty evidence).^[5]

India — the TSDF perspective (Sethi 2026)

• OTC topical corticosteroid misuse is a dominant regional trigger: 64.6% of a consecutive TSDF cohort obtained steroids without prescription, most often on pharmacist recommendation; clobetasol propionate led (44.8%); mean use 13.65 months.^[22]
• Counselling priority — identify the OTC product (fixed-dose combination and "fairness" creams included) and discontinue it.^[22]
• Treatment ladder mirrors the international standard; the study authors call for stricter regulation of potent steroids and bans on irrational fixed-dose combinations.^[22]

Australasian perspective

• No region-specific Australasian POD guideline was identified in this review; practice follows the international ladder (zero therapy first, topicals for moderate disease, oral tetracycline for severe — Mokos 2015).^[6]
• Roflumilast 0.3% is emerging (Domingues 2026 — an illustrative single case, not a case series).^[10]

Gray 2022 — Cochrane / JEADV systematic review

The 2022 Gray systematic review in J Eur Acad Dermatol Venereol is the highest-quality evidence synthesis to date:^[2]

• Included studies — "Eleven studies representing 733 participants"; GRADE certainty assessment applied; seven databases searched to Feb 2021.^[2]
• Oral tetracycline — "may improve physician-reported severity of POD from day 20 onwards (low certainty evidence)"; adverse effects "may include abdominal discomfort, facial dryness and pruritus".^[2]
• Pimecrolimus cream — "may improve physician-reported severity slightly after 4 weeks of treatment (MD -0.49, 95% CI -1.02 to 0.04, n = 164, low certainty evidence)"; adverse effects "may include erythema, herpes simplex virus infection, burning and pruritus".^[2]
• Azelaic acid gel — "may result in no change in either physician- or patient-reported severity after 6 weeks of treatment".^[2]
• Praziquantel ointment and clindamycin/benzoyl peroxide — effects "very uncertain".^[2]
• Bottom line — "The body of evidence to inform treatment of POD currently consists of low and very low certainty evidence for important outcomes"; trials are needed, including in children and low-middle income countries.^[2]
• The review reports no trial evidence for metronidazole, ivermectin, isotretinoin, or "zero therapy" — those recommendations rest on the reviews and cohorts above (Mokos; Tempark; Ollech; Guarda).^{[6][5][8][11]}

The Demodex controversy

The role of Demodex mites is correlated but not proven causal; Demodex "are believed to contribute to the pathogenesis of both rosacea and demodicosis", and a density >5 mites/cm² on SSSB defines infestation.^[20] Eradication (topical, or with a single oral dose of ivermectin) helped one treatment-resistant childhood granulomatous case.^[27] Current synthesis: co-factor, not proven cause.^[1]

The fluoride toothpaste controversy

The role of fluoridated toothpaste is historically reported but methodologically weak. The original observations in the 1970s-1980s were anecdotal case series; subsequent controlled studies have not consistently reproduced the association. The current consensus is that fluoridated toothpaste is not a primary cause but may be a perpetuator in some patients; a 4-week trial of non-fluoride toothpaste is reasonable in refractory disease; a modern case report documents POD "related to the use of highly fluoridated toothpaste commenced to control dental caries" (Peters 2013).^[16]

Regional and cultural differences

• South Asia (India, Pakistan, Bangladesh, Sri Lanka, Nepal) — TSDF endemic; OTC topical corticosteroid misuse; counselling priority.
• East Asia (Korea, Japan, mainland China) — multi-step skincare and "fairness" products with unlabelled steroids.
• Africa (sub-Saharan, North Africa) — TSDF via OTC; granulomatous variant (FACE) over-represented.
• Latin America — compounded fairness creams; melasma treatments with unlabelled steroids.
• Gulf (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman) — South Asian diaspora; compounded fairness creams.
• North America / Western Europe / Australasia — prescribed topical corticosteroid misuse (chronic facial eczema); cosmetic / skincare barrier disruption. ^[1]

Exam Pearls and High-Yield Minutiae

^[1]

Mnemonics

^{[1] [1] [5] [6] [1]}

Single best answer (SBA) rehearsal questions (the examiner's mental map)

1. A 32-year-old woman presents with 3 months of grouped erythematous papules and papulopustules around the mouth, with sparing of the vermilion border. She has been applying a potent topical corticosteroid cream for "eczema" for 6 months. What is the most appropriate first step? Answer: Discontinue the topical corticosteroid ("zero therapy") and counsel on the expected rebound — corticosteroid cream can improve the picture, but the rebound phenomenon usually develops after cessation; escalate to topical metronidazole, erythromycin, or pimecrolimus for moderate disease and subantimicrobial-dose oral tetracycline for severe disease.^[5][6]

2. A 6-year-old Afro-Caribbean boy has monomorphic reddish-brown papules around the mouth and eyes. A biopsy shows an upper dermal, perifollicular granulomatous infiltrate. What is the diagnosis? Answer: Granulomatous perioral dermatitis (Facial Afro-Caribbean Childhood Eruption, FACE). Treat with topical metronidazole and oral erythromycin. ^[1]

3. A 28-year-old woman with asthma on inhaled fluticasone has perioral papules. What is the most likely cause? Answer: Inhaled corticosteroid deposition. Counsel on mouth-rinsing and spacer use; consider non-steroid preventer. ^[1]

4. A 35-year-old pregnant woman develops perioral papules. Which treatment is contraindicated? Answer: Tetracyclines (tooth discolouration, bone growth retardation) and isotretinoin (teratogenic). Use topical metronidazole or azelaic acid first-line. ^[1]

5. A 40-year-old man with perioral papules and a positive patch test to balsam of Peru. What is the most likely diagnosis? Answer: Allergic contact dermatitis (not periorificial dermatitis). Counsel on allergen avoidance. ^[1]

6. A 25-year-old woman with perioral papules and perioral comedones. What is the most likely diagnosis? Answer: Acne vulgaris (with perioral involvement). Note the comedones; periorificial dermatitis has NO comedones. ^[1]

7. A 50-year-old woman with perioral papules, telangiectasia, and flushing after alcohol. What is the most likely diagnosis? Answer: Papulopustular rosacea. Periorificial dermatitis typically lacks telangiectasia and flushing. ^[1]

8. A child with perioral papules and a skin scraping showing 12 Demodex mites per cm². What is the most likely diagnosis? Answer: Demodicosis (or rosacea overlap). Treat with topical ivermectin 1% or oral ivermectin. ^[1]

9. A 60-year-old man with a single chronic perioral plaque that has not responded to therapy. What is the next step? Answer: Biopsy — any chronic single-site lesion unresponsive to therapy needs histology (exclude skin cancer; general dermatology safety principle).

10. A 9-year-old boy with treatment-resistant granulomatous periorificial dermatitis despite topical therapy and inhaled-steroid withdrawal. Which systemic options have recent support? Answer: Oral clarithromycin (95.4% [41/43] cleared at 6 months in a childhood granulomatous POD cohort); topical or single-dose oral ivermectin (case level); refractory disease has resolved with oral isotretinoin ± methotrexate (case level).^[23][27][24]

Red Flags

Exam application bank (NEET-PG / INICET)

One-line answer

Periorificial (perioral) dermatitis is a common inflammatory facial eruption of grouped erythematous micropapules and papulopustules clustered around the orifices — perioral (most common), perinasal, and periocular — with the HALLMARK sparing of the vermilion border (the lips themselves are unaffected, separated from the eruption by a narrow 1-2 mm Grenz zone of clinically normal skin). The dominant trigger is chronic topical corticosteroid use on the face (over-the-counter misuse is endemic in South Asia and produces the so-called TOPICAL STEROID DAMAGED FACE / TSDF picture); cessation causes a rebound flare (the rash worsens before it improves). Other precipitants include inhaled / nasal corticosteroids (asthma, allergic rhinitis — deposition around the mouth and nose), fluoridated toothpaste, occlusive cosmetics and heavy moisturisers, sodium-lauryl-sulphate cleansers, physical sunscreens, and — debatably — Demodex

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Periorificial dermatitis.

^[1]

References28ShowHide

1. [1]Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management J Cosmet Dermatol, 2021.PMID 33751778
2. [2]Gray NA, Tod B, Rohwer A, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review J Eur Acad Dermatol Venereol, 2022.PMID 34779023
3. [3]Acevedo-Fontanez LA, Sánchez-Feliciano A, Ershadi S, et al. Periorificial dermatitis: Pathophysiology, diagnosis, and management J Am Acad Dermatol, 2026.PMID 41197738
4. [4]Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids J Am Acad Dermatol, 2006.PMID 16384751
5. [5]Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options Am J Clin Dermatol, 2014.PMID 24623018
6. [6]Mokos ZB, Kummer A, Mosler EL, et al. Perioral dermatitis: still a therapeutic challenge Acta Clin Croat, 2015.PMID 26415314
7. [7]Kellen R, Silverberg NB. Pediatric periorificial dermatitis Cutis, 2017.PMID 29360899
8. [8]Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis J Am Acad Dermatol, 2020.PMID 32032693
9. [9]Chiriac A, Chiriac AE, Madke B, et al. Periorificial dermatitis in infants and preschoolers - a narrative review Eur J Pediatr, 2025.PMID 39825187
10. [10]Domingues E. The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission J Clin Aesthet Dermatol, 2026.PMID 42239843
11. [11]Guarda D, Marquez P, Bascuñan G, Montane C. Recalcitrant Perioral Dermatitis Successfully Controlled With Low-Dose Isotretinoin: A Case Report Cureus, 2026.PMID 42037824
12. [12]Yang CS, Teeple M, Muglia J, Robinson-Bostom L. Inflammatory and glandular skin disease in pregnancy Clin Dermatol, 2016.PMID 27265071
13. [13]Kim YJ, Shin JW, Lee JS, et al. Childhood granulomatous periorificial dermatitis Ann Dermatol, 2011.PMID 21909215
14. [14]Hoepfner A, Marsela E, Clanner-Engelshofen BM, et al. Rosacea and perioral dermatitis: a single-center retrospective analysis of the clinical presentation of 1032 patients J Dtsch Dermatol Ges, 2020.PMID 32469453
15. [15]Tolaymat L, Syed HA, Hall MR. Perioral Dermatitis StatPearls [Internet], 2026.PMID 30247843
16. [16]Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice: a case report and review of literature Aust Dent J, 2013.PMID 23981221
17. [17]Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf, 2016.PMID 26680308
18. [18]Smith GN, Gemmill I, Moore KM. Management of tick bites and lyme disease during pregnancy J Obstet Gynaecol Can, 2012.PMID 23231847
19. [19]Ivask M, Kurvits K, Uusküla M, et al. Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia Drugs Real World Outcomes, 2024.PMID 37462893
20. [20]Forton F, Seys B, Marchal JL, et al. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy Br J Dermatol, 1998.PMID 9580800
21. [21]Nasimi M, Bandani S, Kamyab K, et al. Clinical and Histopathological Insights Into Lupus Miliaris Disseminatus Faciei: A Review of 70 Cases J Cutan Pathol, 2025.PMID 39945109
22. [22]Sethi P, Maheshwari K, Arora E, et al. Topical Steroid and Fairness Cream Abuse in Facial Dermatoses: A Cross-Sectional Study at a Tertiary Care Center in Western Uttar Pradesh Cureus, 2026.PMID 41959968
23. [23]Xiao Y, He J, Chen A, et al. Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study JAAD Int, 2025.PMID 41079392
24. [24]Jagdeo M, Keddy-Grant J. Treatment-resistant granulomatous periorificial dermatitis in a 14-year-old female: Resolution after oral isotretinoin and methotrexate - A case report SAGE Open Med Case Rep, 2026.PMID 42111043
25. [25]Aksu Arıca D, Ozturk Topcu T, Baykal Selçuk L, et al. Assessment of demodex presence in acne-like rash associated with cetuximab Cutan Ocul Toxicol, 2017.PMID 27802779
26. [26]Forkel S, Schubert S, Corvin L, et al. Contact allergies to dental materials in patients Br J Dermatol, 2024.PMID 38123140
27. [27]Correia MP, Fernandes S, de Vasconcelos P, et al. Childhood granulomatous periorificial dermatitis: Ivermectin as a novel therapeutic approach Dermatol Online J, 2026.PMID 42246357
28. [28]Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children? J Cutan Med Surg, 2009.PMID 19298782